Australia Pharmaceuticals Tenders

Australia's pharmaceuticals market is a multi-billion dollar industry, expected to reach US$9.78 billion in 2023 and growing at an annual rate of 6.55%.
The market is driven by an aging population, increasing chronic diseases, and rising government expenditure on healthcare.
Key segments include prescription drugs, over-the-counter medications, generics, and patented drugs.

The Australian government is a major procurer of pharmaceuticals, accounting for around 30% of the market.
Procurement is centralized through the Department of Health, which uses a tendering process to select suppliers.
The government prioritizes affordability, quality, and innovation in its procurement decisions.

The Australian government procures a wide range of pharmaceuticals, including:
Prescription drugs for chronic conditions such as diabetes, cancer, and cardiovascular disease
Vaccines
Blood products
Medical devices
The government also procures pharmaceutical services, such as research and development, manufacturing, and distribution.

The Department of Health is the main authority for pharmaceuticals procurement in Australia.
The Pharmaceutical Benefits Advisory Committee (PBAC) advises the government on which drugs to list on the Pharmaceutical Benefits Scheme (PBS).
The Therapeutic Goods Administration (TGA) regulates the safety and quality of pharmaceuticals in Australia.

Some of the top winners of Australian government pharmaceuticals procurement contracts include:
Pfizer
GlaxoSmithKline
Merck
Johnson & Johnson
AbbVie
These companies supply a wide range of pharmaceuticals to the Australian government.

Tags -
Australia pharmaceutical tenders, Australia pharmaceuticals bids contracts, Australia pharmaceutical government tenders, Australia pharmaceutical global tenders, Australia free pharmaceutical tenders, Australia drugs tenders, Australia medicine tenders, Australia generic medicine tenders